IMRA Share Price | Enliven Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Enliven Therapeutics, Inc.?

Market Cap: As of Jun 18, Enliven Therapeutics, Inc. has a market capitalization of 1,069.71 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Enliven Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -94.83 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 309.85 million and total assets of 325.76 million.

Q: What does Enliven Therapeutics, Inc. do?

Overview:Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for rare inherited genetic disorders of hemoglobin, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Micro Cap.Financial Snapshot:Most recent Net Profit: -29 Million (Quarterly Results - Mar 2025)Market cap: USD 1,069.71 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making)Dividend Yield: 0.00%Debt Equity: -1.00Return on Equity: -33.20%Price to Book: 3.71Contact Details:Address: 116 HUNTINGTON AVENUE, 6TH FLOOR, BOSTON MA : 02116Tel: 1 617 2062020Website: https://imaratx.com/

Q: Is Enliven Therapeutics, Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for Enliven Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating positive momentum. The daily moving averages are mildly bullish, supporting the overall bullish stance. However, the weekly KST and Bollinger Bands present some bearish signals, and the RSI shows no signal on both weekly and monthly time frames. In terms of performance, the stock has underperformed the S&P 500 across multiple periods, with a year-to-date return of -15.51% compared to the S&P 500's 16.30%, and a one-year return of -31.20% versus the S&P 500's 19.89%. Overall, the current technical stance is bullish but with caution due to mixed signals from some indicators.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

275.42 k

Shareholding (Dec 2025)

FII

14.42%

Held by 72 FIIs

DII

Held by 96 DIIs

Promoter

24.57%

How big is Enliven Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Enliven Therapeutics, Inc. has a market capitalization of 1,069.71 million, with net sales of 0.00 million and a net profit of -94.83 million over the latest four quarters. The company reported shareholder's funds of 309.85 million and total assets of 325.76 million as of Dec 24.

View full answer

What does Enliven Therapeutics, Inc. do?

22-Jun-2025

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare inherited genetic disorders of hemoglobin. It has a market cap of approximately $1.07 billion and reported a net profit loss of $29 million as of March 2025.

View full answer

Who are in the management team of Enliven Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Enliven Therapeutics, Inc. includes Independent Chairman Mr. David Mott, President and CEO Dr. Rahul Ballal, and several independent directors: Mr. Edward Conner, Ms. Mette Agger, Dr. David Bonita, Mr. Mark Chin, and Dr. Barbara Dalton.

View full answer

Is Enliven Therapeutics, Inc. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, Enliven Therapeutics, Inc. shows a bullish technical trend with positive momentum from MACD and moving averages, but caution is advised due to mixed signals from KST and Bollinger Bands, alongside underperformance compared to the S&P 500.

View full answer

Compare Enliven Therapeutics, Inc. with Similar Stocks

Vera Therapeutics, Inc.Avid Bioservices, Inc.Editas Medicine, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 1,638 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.00

Return on Equity

-20.42%

Price to Book

3.44

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-30 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

88.45%

6 Months

62.32%

1 Year

47.77%

2 Years

68.56%

3 Years

38.44%

4 Years

289.38%

5 Years

-15.45%

Enliven Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-199.67%

EBIT to Interest (avg)

-67.97

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.00

Sales to Capital Employed (avg)

Tax Ratio

0.25%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

0.10%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.44

EV to EBIT

-10.34

EV to EBITDA

-10.37

EV to Capital Employed

-1099.20

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-20.42%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bearish

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 38 Schemes (89.08%)

Foreign Institutions

Held by 72 Foreign Institutions (14.42%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -28.02% vs -19.59% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-34.20",
          "val2": "-26.80",
          "chgp": "-27.61%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-29.70",
          "val2": "-23.20",
          "chgp": "-28.02%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -16.52% vs -24.30% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-119.40",
          "val2": "-104.20",
          "chgp": "-14.59%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.90",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-103.70",
          "val2": "-89.00",
          "chgp": "-16.52%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-34.20

-26.80

-27.61%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-29.70

-23.20

-28.02%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -28.02% vs -19.59% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-119.40

-104.20

-14.59%

Interest

0.00

Exceptional Items

0.00

0.90

-100.00%

Consolidate Net Profit

-103.70

-89.00

-16.52%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -16.52% vs -24.30% in Dec 2024

All Annual Results

Company CV

About Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Imara, Inc. is a clinical-stage biopharmaceutical company. The Company is developing and commercializing therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. The Company’s product pipeline include IMR-687, which is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease (SCD), and beta-thalassemia. Its IMR-687 is a selective, small molecule inhibitor of phosphodiesterase-9 (PDE9). The Company is conducting a Phase 2a clinical trial of IMR-687 in adult patients with SCD and a Phase 2b clinical trial for the treatment of patients with beta-thalassemia.

Company Coordinates

Company Details

116 HUNTINGTON AVENUE, 6TH FLOOR , BOSTON MA : 02116

Tel: 1 617 2062020

https://imaratx.com/

Registrar Details